Skip to content

The Effect of Nutrition for the Colorectal Cancer Patients Receiving Chemotherapy-randomized Controlled Study

The Effect of Nutrition for the Colorectal Cancer Patients Receiving Chemotherapy-randomized Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04567459
Enrollment
100
Registered
2020-09-28
Start date
2021-01-27
Completion date
2021-02-22
Last updated
2021-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

colorectal cancer, Chemotherapy, Nutrition, Sarcopenia

Brief summary

We use clinical trial to explore the effect of nutrition support in colorectal cancer patients receiving postoperative adjuvant chemotherapy.

Detailed description

Colorectal cancer is the most common cancer in Taiwan. Side effects induced by postoperative adjuvant chemotherapy will affect nutrition status and may delay treatment and affect prognosis. Sarcopenia may be noted in some patients and increase the toxicities of chemotherapy. The studies of intervention include nutrition consultant and treatment like protein, fish oil or Vitamin D supplement. Premium amino acids include multiple amino acids and organic Selenium and have effect in inhibition of tumor proliferation according to colorectal cancer cell and animal experiments.

Interventions

DIETARY_SUPPLEMENTPremium Amino Acids

after Chemotherapy ang surgery one pack of Premium Amino Acids in the morning and evening

Sponsors

Hanben Enterprise
CollaboratorUNKNOWN
Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 20 * Radical operation for stage III and stage II with high risk colorectal cancer * Agree to join the trial and sign the informed consent form

Exclusion criteria

* Unable to receive chemotherapy * Unstable vital sign * Not suitable after evaluation by Principal Investigator

Design outcomes

Primary

MeasureTime frameDescription
Assessment of adverse event2 weeks after chemotherapyEvaluation of adverse event(Grade 1-4) between control group and experimental group before every chemotherapy(total 12 times)
1)Nutrition assessment2 weeks after chemotherapyalbumin level between two group before every chemotherapy(total 12 times)
2)Nutrition assessment2 weeks after chemotherapypre-albumin level between two group before every chemotherapy(total 12 times)
1)Sarcopenia assessment muscle powerAt 1st cycle of chemotherapy (each cycle is 2 weeks).1-1)Assessment with Grip strength(Kg)
2)Sarcopenia assessment muscle powerAt 1st cycle of chemotherapy (each cycle is 2 weeks).2-1)Assessment with ASM/heigh2(Kg/m2)
3)Sarcopenia assessmentAt 1st cycle of chemotherapy (each cycle is 2 weeks).3-1)Assessment with speed(m/s)
4)Sarcopenia assessmentAt 1st cycle of chemotherapy (each cycle is 2 weeks).4-1)Assessment with DXA(g/cm2)
5)Sarcopenia assessmentAt 6th cycle of chemotherapy (each cycle is 2 weeks).5-1)Assessment with abdominal CT

Countries

Taiwan

Contacts

Primary ContactWan-Hsiang Hu, M.D.
gary.hu0805@gmail.com886-975056227

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026